We develop topical recombinant proteins for anti-wrinkle markets not served by Botox because of aversion to needles and toxicity concerns.
We are developing a new class of topical muscle relaxants for the rapidly growing $3 billion anti-wrinkle market. Our compounds are smaller and more stable than botulinum toxins, capable of transdermal delivery and producing transient muscle paralysis. Our first product is a topical formulation, which can be sold in the US without pre-market approval. We also plan to develop pharmaceutical compounds for chronic back pain and muscle spasms.